Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Since the start of the global spread of coronavirus disease (COVID-19) pandemic, cancer patients were identified as a specifically susceptible subgroup of the patient population. Several reports have shown that cancer patients have an increased risk of both contracting the infection and of experienc...

Full description

Bibliographic Details
Main Authors: Chiara Burgaletto, Oronzo Brunetti, Antonio Munafò, Renato Bernardini, Nicola Silvestris, Giuseppina Cantarella, Antonella Argentiero
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
immuno-oncologics
immune response
cancer therapy
drug safety
Online Access:https://www.mdpi.com/2072-6694/13/8/1906

Similar Items

Similar Items